DYRK1A and prostate carcinoma: Similarly, high expression of miR-129-5P in prostate cancer downregulates the level of a serine/threonine-specific protein kinase (CAMK2N1), and targeting miR-129-5P sensitizes patients with prostate cancer to the chemotherapy drug docetaxel (Wu et al., 2020).